Clinical trials: Multisystem Inflammatory Syndrome in Children
Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This will provided long-term safety and efficacy data for ACZ885 (a fully human anti-interleukin-1β [anti-IL-1β] monoclonal antibody) given as an injection subcutaneously in patients who participated in the CACZ885A2102…
- Conditions
- Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT00685373
- Testing
- Canakinumab (ACZ885)
- Where
- 28 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- Novartis
Myocarditis, Pediatric Inflammatory Multisystem Syndrome
Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
Acquired inflammatory or infectious cardiac diseases, in pediatrics, include Kawasaki disease, myocarditis, and Covid-19-related Pediatric Multisystemic Inflammatory Syndrome (PIMS).
- Conditions
- Myocarditis, Pediatric Inflammatory Multisystem Syndrome, Kawasaki Disease
- Trial name
- NCT05911386
- Testing
- study of biological samples and echocardiographic data and link with need of hemodynamic support
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Long Covid19, COVID-19 Pneumonia
Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan
This project will study severe COVID-19 related factors, host genes, biomarkers, and prognosis of severe encephalitis in children, and conduct: 1.
- Conditions
- Long Covid19, COVID-19 Pneumonia, Multisystem Inflammatory Syndrome in Children
- Trial name
- NCT05582512
- Testing
- sequelae tracking
- Where
- Taiwan
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
MIS-C Associated With COVID-19, COVID-19
Study of Virus-specific Lymphocytic Cell Populations in Non-invasive Nasal Mucosa Samples of MIS-C Patients
The aim of the study is to make an accurate assessment of immune cells obtained from nasal mucosa and peripherial blood of MIS-C patients during the disease and the period of health.
- Trial name
- NCT05560906
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Medical University of Warsaw
Covid19, Multisystem Inflammatory Syndrome in Children
AT1001 for the Treatment of COVID-19 Related MIS-C
The primary aim of this study is to evaluate the efficacy and safety of AT1001 versus placebo in pediatric patients with SARS-CoV-2 infection who experience early signs of MIS-C and are at high risk of progression.
- Trial name
- NCT05022303
- Testing
- Larazotide Acetate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Covid19, MIS-C Associated With COVID-19
Pediatric COVID Outcomes Study (PECOS)
This is a multisite prospective observational study to evaluate the clinical sequelae of symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population, including…
- Conditions
- Covid19, MIS-C Associated With COVID-19, MIS-C Multisystem Inflammatory Syndrome in Children, SARS-CoV2 Infection
- Trial name
- NCT04830852
- Where
- 2 sites in United States
- Volunteers
- 1,097 people, healthy volunteers welcome
- Sponsor
- Children's National Research Institute
COVID-19-Associated Encephalitis, Multisystem Inflammatory Syndrome in Children
Investigation of Prognostic Biomarkers, Host Factors and Viral Factors for COVID-19 in Children
Background and objective From this April, there was a COVID-19 outbreak in Taiwan. The first fatal case of pediatric COVID-19 encephalitis was reported on April 19, 2022 and fatal fulminant cerebral edema in other 4 children with…
- Trial name
- NCT05576714
- Testing
- delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Multisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection
Cardiovascular Assessment 5 Years After MIS-C
Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system.
- Trial name
- NCT07659847
- Where
- Poland
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Multisystem Inflammatory Syndrome in Children (MIS-C)
Quality of Life in Children After Multisystem Inflammatory Syndrome in Children
The aim of this observational study is to assess whether Multisystem Inflammatory Syndrome (MIS-C) in children affects their quality of life.
- Trial name
- MIS-C (NCT07126028)
- Where
- Croatia
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Kristina Lah Tomulić
Myocarditis
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
The purpose of this study is to learn about the safety and effects of the vaccine (called COMIRNATY) for the potential prevention of COVID-19. This study is seeking participants who: 1. Are age <21 years. 2.
- Trial name
- NCT05295290
- Testing
- Cardiac Imaging
- Where
- 18 sites in United States
- Volunteers
- 319 people
- Sponsor
- Pfizer
Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
Contrast Enhanced Ultrasound in COVID-19
Initial data from COVID-19 patients suggests that one of the primary causes of death is significant endothelial injury leading to blood clotting and impaired multiorgan microvascular perfusion.
- Trial name
- NCT04640038
- Testing
- Sulfur hexafluoride lipid-type A microspheres
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Children's Hospital of Philadelphia
Multisystem Inflammatory Syndrome in Children, COVID-19
COVID-19: Immunological Mechanisms in Multisystem Inflammatory Syndrome in Children
This study seeks to explore immunological mechanisms in patients with Multisystem Inflammatory Syndrome in Children (MIS-C) to improve the understanding of this pathogenesis of this disease.
- Conditions
- Multisystem Inflammatory Syndrome in Children, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT05334134
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Covid19; MIS-C
Coronavirus-19 (COVID-19) and Related Outcomes in School Aged Children (ABC Health Outcomes in Children)
This is a prospective, observational study with a primary objective of determining the incidence of non-severe and severe COVID-19, including MIS-C, among eligible children who are diagnosed with COVID-19 and consent (or assent)…
- Trial name
- NCT04757831
- Volunteers
- healthy volunteers welcome
- Sponsor
- Duke University
COVID-19, MIS-C Associated With COVID-19
Exercise Fatigue Parameters and Endothelial Function in Pediatric Patients With a History of COVID-19 Infection or MIS-C
Acute coronavirus disease 2019 (COVID-19) infection can include cardiac and pulmonary manifestations as well as post-infectious complications such as multisystem inflammatory syndrome (MIS-C), also known as pediatric inflammatory…
- Trial name
- NCT05205642
- Testing
- Cardiopulmonary exercise test (CPET), Peripheral Arterial Tonography (PAT) using the EndoPAT™ device, Endothelin
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Rambam Health Care Campus
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C)
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
The primary objectives of this study are: To determine the proportion of children with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications after infection with…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19)
- Trial name
- PRISM (NCT04588363)
- Testing
- SARS-CoV-2 and/or MIS-C Exposure
- Where
- 20 sites in United States
- Volunteers
- 244 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multisystem Inflammatory Syndrome-Children
MIS-C Comparative Effectiveness Study
In March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus.
- Trial name
- MISTIC (NCT04898231)
- Testing
- Infliximab, Anakinra, Methylprednisolone
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- University of California, San Diego
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This trial will provide long-term safety, efficacy and tolerability of ACZ885 in CAPS patients that completed the CACZ885D2307 study
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT01576367
- Testing
- ACZ885
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.
- Trial name
- NCT04456439
- Testing
- Remestemcel-L, Hydrocortisone, Diphenhydramine
- Sponsor
- Mesoblast International Sàrl